CBR1: A Gene Encoding A Protein Involved in Antioxidant and Signaling Pathways

Target Name: CBR1

NCBI ID: G873

CBR1

CBR1: A Gene Encoding A Protein Involved in Antioxidant and Signaling Pathways

Carbonyl Reductase 1 (CBR1) is a gene that encodes a protein involved in the antioxidant response of cells. It is a key enzyme in the cycle of carbonyl reduction, which is a process by which oxygen-carrying molecules in the cell are reduced to carbonyl species. This process is critical for maintaining cellular health and has been implicated in a wide range of cellular processes, including cell growth, apoptosis, and inflammation.

CBR1 is a protein that is expressed in many different tissues and cells throughout the body. It is highly conserved, with significant sequence identity across different species. It is localized to the endoplasmic reticulum, where it is involved in the delivery of proteins for subsequent degradation or degradation via the endoplasmic reticulum-to-endoplasmiculum (ER-ER) route.

One of the unique features of CBR1 is its role in the antioxidant response. It is a key enzyme in the cycle of carbonyl reduction, which involves the transfer of a carbonyl group from reduced cytosine molecules to a reduced carbonyl group on cysteine residues. This process generates reactive oxygen species (ROS) that can damage cellular components and contribute to cellular stress and dysfunction.

CBR1 is also involved in the regulation of cellular signaling pathways. It has been shown to play a role in the negative regulation of cell proliferation, and to mediate the effects of various signaling pathways on cellular behavior. For example, CBR1 has been shown to play a negative role in the regulation of the PI3K/Akt signaling pathway, which is involved in cell survival and proliferation.

CBR1 is a potential drug target because of its involvement in the antioxidant response and its role in cellular signaling pathways. Its antioxidant properties make it a potential target for compounds that are designed to prevent oxidative stress and promote cellular health. Additionally, its role in cell signaling pathways makes it a potential target for compounds that are designed to modulate cellular signaling pathways and improve cellular function.

In conclusion, CBR1 is a gene that encodes a protein involved in the antioxidant response and cellular signaling pathways. Its unique role in the cycle of carbonyl reduction makes it a potential drug target for compounds that are designed to prevent oxidative stress and promote cellular health. Further research is needed to fully understand the functions of CBR1 and its potential as a drug target.

Protein Name: Carbonyl Reductase 1

Functions: NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol (PubMed:18449627, PubMed:15799708, PubMed:17912391, PubMed:7005231, PubMed:1921984, PubMed:17344335, PubMed:18826943). Can convert prostaglandin E to prostaglandin F2-alpha (By similarity). Can bind glutathione, which explains its higher affinity for glutathione-conjugated substrates. Catalyzes the reduction of S-nitrosoglutathione (PubMed:18826943, PubMed:17344335). In addition, participates in the glucocorticoid metabolism by catalyzing the NADPH-dependent cortisol/corticosterone into 20beta-dihydrocortisol (20b-DHF) or 20beta-corticosterone (20b-DHB), which are weak agonists of NR3C1 and NR3C2 in adipose tissue (PubMed:28878267)

The "CBR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets